Check-Cap (NASDAQ:MBAI) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Check-Cap (NASDAQ:MBAI) to a hold rating in a research report report published on Tuesday,Zacks reports.

Several other research firms have also recently weighed in on MBAI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Check-Cap in a report on Tuesday, July 21st. Northland Securities began coverage on Check-Cap in a research note on Monday. They set an “outperform” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Check-Cap Price Performance

NASDAQ MBAI opened at $3.54 on Tuesday. The company’s 50 day simple moving average is $7.04 and its two-hundred day simple moving average is $9.36. Check-Cap has a 1 year low of $3.34 and a 1 year high of $27.44. The stock has a market capitalization of $4.89 million, a PE ratio of -0.25 and a beta of 0.67.

Check-Cap Company Profile

Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.

The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body.